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A. Van Hoof, MD, PhD6, D. Dierickx, MD, PhD7, G. Verhoef, MD, PhD7, T. Tousseyn, MD, PhD8, A. Janssens, 
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Waldenström’s macroglobulinaemia is a B-cell disorder characterised by bone marrow infiltration with 
lymphoplasmacytic cells, along with demonstration of an IgM monoclonal gammopathy in the blood. 
This condition belongs to the lymphoplasmacytic lymphomas as defined by the World Health Organization 
classification (ICD-0 code 9671/3). Approximately one-fourth of patients are asymptomatic. Clinical features 
of the symptomatic patients are diverse and may relate to overall disease burden (such as peripheral 
blood cytopaenias, organomegaly and constitutional symptoms) or may be directly attributable to the IgM 
paraprotein. The latter include hyperviscosity syndrome, amyloidosis, peripheral neuropathy and cold 
haemagglutinin. Therapeutic options have traditionally involved alkylating agents, nucleoside analogues, and 
rituximab, either as single therapy or in combination. However, emerging new data on combination therapy 
as well as novel agents have shown encouraging results. This report provides the Belgian Hematology 
Society guidelines according to recent clinical studies.
(Belg J Hematol 2015;6(4):142-50)
Introduction
Waldenström’s macroglobulinaemia (WM) is a low grade 
B-cell lymphoma characterised primarily by bone mar-
row infiltration with lymphoplasmacytic cells, along 
with demonstration of a serum IgM monoclonal gammo-
pathy of any concentration. This condition belongs to 
the lymphoplasmacytic lymphomas (LPL) as defined 
by the World Health Organization classification. Most 
cases of LPL are WM, with less than 5% of cases being 
IgA, IgG and non secreting LPL. WM has an overall 
incidence of approximately three per million persons per 
year.1 The median age varies between 63-68 years, and 
55-70% are male.2 WM is predominantly a sporadic 
disease, but up to 20% of patients has at least a first 
degree relative with a B-cell neoplasm. Currently, sys-
tematic screening of family members is not indicated. 
The main risk factor for the development of WM is a 
pre-existing IgM-monoclonal gammopathy of undeter-
mined significance (MGUS) with an estimated annual 
progression rate of 1.5%.3 Patients with a personal or 
family history of an autoimmune, inflammatory disor-
der or a history of hepatitis C (HCV) exposure have 
an increased risk to develop WM. This association is 
particularly strong for Sjögren’s syndrome and auto-
immune haemolytic anaemia (AIHA).4,5
Clinical features
WM is a heterogeneous disease in terms of clinical 
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manifestations, with 25% of patients being asympto-
matic. Morbidity associated with WM is typically due 
to tissue infiltration by neoplastic cells and/or the 
physicochemical and immunologic properties of the 
monoclonal IgM (Table 1). The most common clinical 
presentation is cytopaenia, specifically anaemia related 
to massive bone marrow infiltration by tumour cells. 
Fatigue is also a common symptom that is multifactorial, 
caused partially by the underlying anaemia. Patients 
may present with symptoms of hyperviscosity related 
to elevated IgM levels leading to headache, blurry vision 
and/or epistaxis. Unlike most indolent lymphomas, 
splenomegaly and lymphadenopathy are present in a 
minority of patients (15%).1 Renal function should be 
carefully evaluated in WM patients because of possible 
light chain or amyloid deposition, as well as parenchymal 
involvement by lymphoplasmacytic cells. 
Diagnostic workup
To establish a diagnosis of WM, it is necessary to demon-
strate an IgM monoclonal protein along with histological 
infiltration of bone marrow by lymphoplasmacytic cells. 
There is no minimal serum IgM level or a minimal per-
centage of bone marrow infiltration to establish the diag-
nosis of WM, because patients can be symptomatic 
even at low levels of IgM or with minor bone marrow 
involvement. 
Laboratory assessment
IgM paraprotein should be demonstrated by serum 
protein electrophoresis and quantitated by densitometry. 
Concentration of IgG and IgA should also be measured 
at diagnosis because low IgA and IgG levels are often 
present and may contribute to recurring infections.1 
Serum IgA and IgG levels seldom return to normal 
after treatment, even in good remissions. This may 
be a reflection of a constitutional defect in plasma cell 
development.6
The value of serum free light chain (SFLC) and Hevylite™ 
assays (HLC) have not been established and are not 
essential for the routine assessment of WM patients.7,8
Cold agglutinins, cryoglobulins, and anti-myelin asso-
ciated glycoprotein (anti-MAG) should be performed 
according to the clinical scenario. 
Screening for hepatitis B (HBV) and HCV is required 
prior to the introduction of rituximab-containing treat-
ments and because of the possible association between 
HCV, WM and cryoglobulinaemia. 
Bone marrow assessment
The demonstration of bone marrow infiltration by a 
lymphoplasmacytic cell population is essential to the 
diagnosis of WM. This is characterised by small lym-
phocytes with evidence of plasmacytoid/plasma cell 
differentiation, including the presence of intranuclear 
pseudoinclusions (also called Dutcher bodies). A trephine 
biopsy is recommended to assess the degree and pattern 
of infiltration accurately and morphology should be 
supported by immunophenotypic studies. Phenotyping 
is usually performed on the B-cell component of the 
disease and cells express pan B-cell markers including 
CD19, CD20, CD22 and surface IgM, but lack CD23, 
Table 1. Morbidities mediated by the monoclonal IgM protein in WM.
Diagnostic condition/ Property of IgM monoclonal protein Clinical manifestations
Hyperviscosity Headaches, blurred vision, epistaxis, retinal hemorrhages, 
leg cramps, impaired mentation, intracranial hemorrhage
Cryoglobulinaemia Raynaud phenomenon, purpura, cold urticaria, arthralgias, renal failure
Peripheral neuropathies (antibodies to myelin-associated 
glycoprotein (MAG), ganglioside M1(GM1), cryoglobulinaemia)
Sensorimotor neuropathies, painful neuropathies, ataxia
Cold agglutinins Hemolytic anaemia, Raynaud phenomenon, livedo reticularis
Tissue deposition as amorphous aggregates Bullous skin disease, papules, Scnitzler syndrome, diarrhea, 
malabsorption, proteinuria, renal failure
Amyloidosis Fatigue, weight loss, edema, hepatomegaly, macroglossia, 
organ dysfunction: heart, hepatic and renal failure, peripheral and 
autonomic neuropathy 
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CD10, CD5 and cytoplasmic Ig. Variations from this 
phenotypic profile can occur and up to 20% of cases 
may express CD5, CD10, or CD23. In such cases, 
chronic lymphocytic leukaemia (CLL) and marginal 
zone cell lymphoma (MZL) should be excluded and 
expression patterns of CD25, CD22 and CD103 may 
be helpful.9,10 Mantle cell lymphoma (MCL) should be 
excluded in case of CD5 positive phenotype. 
Published data on plasma cell immunophenotyping 
in WM suggest that the antigenic myeloma patterns 
(CD19-CD45-CD56+) are not seen in WM plasma 
cells.10 
Cytogenetic and molecular analysis
Among chromosomal abnormalities observed in WM, 
deletion of the long arm of chromosome 6 (6q-) is 
the most frequent, occurring in up to 50% of patients. 
Most of the recurrent abnormalities encountered are 
shared with other indolent B-cell disorders, except for 
the trisomy 4, which is observed in +/- 15-19% of WM 
cases and appears to be unique to this clinical entity.11 
Cytogenetic analysis might therefore be useful to clarify 
the differential diagnosis with cases of IgM myeloma 
or MZL. Prognostic significance of the chromosomal 
alterations remains controversial in WM.11 IgH switch 
region rearrangements (14q32 translocations) are typi-
cally absent in WM and may suggest the diagnosis of 
IgM myeloma.12 Recent publications have demonstrated 
a somatically acquired single point mutation (L265P) 
in the myeloid differentiation primary response gene 
(MYD88) in 90% of patients with WM.12 This aberration 
leads to constitutive activation of the oncogenic nuclear 
factor-kB signalling pathway. The determination of the 
MYD88 mutation status might also help to make the 
differential diagnosis between WM and MZL.13,14 CXCR4 
is a chemokine receptor that promotes survival of WM 
cells. CXCR4 mutations have been reported in roughly 
30% of WM patients.59 Although identification of those 
mutations are not routinely recommended, these patients 
may benefit differentially from novel therapies (see future 
perspective). Deletion of TP53 occurs in a minority of 
patients and appears to define patients with a poor 
outcome, but further evaluation is required before use 
in daily practice.15
Imaging
Baseline computerised tomography (CT) scans (chest, 
abdomen, and pelvis) are recommended in all sympto-
matic patients prior to the start of treatment. There is no 
convincing rationale for the routine use of fluorodeoxy-
glucose positron emission tomography (FDG-PET) scan-
ning, except if histological transformation is suspected.16
Differential diagnosis 
An IgM monoclonal component accompanied by bone 
marrow infiltration with lymphoplasmacytic cells can be 
observed in other B-cell lymphoproliferative disorders, 
such as MCL, MZL and CLL.17
Prognostic scoring system and indication 
for therapy
The International Prognostic Scoring System for WM 
(ISSWM) is based on five key adverse prognostic fea-
tures: age >65 years, haemoglobin (Hb) <11,5 g/dL, 
platelet ≤100x103/mm3, β2 microglobulin >3mg/L and 
paraprotein >70g/L and is presented in Table 2.18 There 
is consensus that ISSWM should be recorded in all 
patients at presentation, but there is no evidence to 
support its use in determining treatment approaches 
for individual patients.
Table 2. International Prognostic Scoring System (IPSS) for Waldenström’s macroglobulinaemia.
Low risk Intermediate risk High risk
Age <65yr >65 yr >65 yr
Hemoglobin≤11,5g/dL 
Platelet≤100x109/L ≤1 factor 2 factors >2 factors
Beta2-microglobulin>3 mg/L
IgM>7g/dL
Survival at 5 yr 87% 68% 36%
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The indications for treatment include constitutional 
symptoms, symptomatic adenopathy or organomegaly, 
disease-related cytopaenia (Hb <10 g/dL, platelet 
<100x103/mm3), hyperviscosity, amyloidosis, symp-
tomatic peripheral neuropathy, symptomatic cryoglo-
bulinemia, or cold-agglutinin disease.19 Initiation of 
therapy should not be based on serum monoclonal 
protein levels as such. Asymptomatic patients may 
have an indolent course for a long period of time, even 
when their monoclonal protein exceeds 30g/L.20 Close 
observation rather than therapy is appropriate for these 
patients (Table 2).
Response assessment
Treatment responses should be defined using the uni-
form treatment response criteria recently updated at 
the VIth international workshop on WM (Table 3).21
The quality of response does appear to affect outcome.22 
One should be careful to use IgM as a surrogate marker 
of disease because of possible fluctuations independent 
of tumour cell killing and because there’s not always an 
association between clinical benefit and IgM response. 
This is particularly observed with the use of newer bio-
logically targeted agents such as rituximab and bor-
tezomib. Rituximab can induce a flare in serum IgM 
levels that may last weeks to months.23 Purine ana-
logues and alkylators selectively deplete the CD20+ 
B-cell component with sparing of the CD138+ plasma 
cell component and induce slow IgM responses. Con-
versely, bortezomib can suppress IgM levels in some 
patients independent of tumour cell killing.24,25
Therefore, besides the serum IgM levels, repeated bone 
marrow biopsy and CT scans should be encouraged to 
refine response assessment and clarify the patient’s 
underlying disease burden. 
Assessment of SFLC and HLC may provide an earlier 
indication of both response and progression, but with-
out prospective evaluation their routine use cannot be 
recommended.8 
Treatment approaches to Waldenström’s 
macroglobulinaemia
To date there's no curative therapy for WM. Treatment is 
started to control symptoms and prevent organ damage. 
Table 3. Response criteria from the VI International Workshop on Waldenström’s macroglobulinaemia.
Response Criteria 
Complete response (CR) Absence of serum monoclonal protein by immunofixation
Normal serume IgM level
No bone marrow involvement
Complete resolution of extramedullary disease i.e., any adenopathy/organomegaly, along with non 
signs or symptoms attribuable to Waldenström’s macroglobulinaemia. 
Very good partial response (VGPR) Monoclonal IgM protein is detectable 
≥90% reduction in serum IgM level from baseline *
Complete resolution of extramedullary disease i.e., any adenopathy/organomegaly, along with non 
signs or symptoms attribuable to Waldenström’s macroglobulinaemia. 
Partial response (PR) Monoclonal IgM protein is detectable 
≥50% but <90% reduction of serum IgM level from baseline*
Rection of extramedullary disease if present at baseline
No new signs or symptoms of active disease 
Minor response (MR) Monoclonal IgM protein is detectable
≥25% but <50% reduction of serum monoclonal IgM level from baseline*
Non new signs or symptoms of active disease 
Stable disease (SD) Monoclonal IgM protein is detectable
<25% reduction and <25% increase in serum IgM level from baseline*
No progression in extramedullary disease
No new signs or symptoms  of active disease 
Progressive disease (PD) ≥25% increase in serum monoclonal IgM level* from lowest nadir (requires confirmation) and/or 
progression in clinical features attributable to the disease 
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Several products have shown to be effective but there’s 
a lack of large prospective, randomised trials. This makes 
it difficult to compare regimens and to set up a general 
approach. The choice of therapy is generally decided 
based upon age, general condition of the patient, the 
severity of the symptoms and eligibility for autologous 
stem cell transplantation (SCT). 
Patients with indolent disease
At least 25% of patients are asymptomatic at the time 
of diagnosis. Patients that do not have constitutional 
symptoms, bulky disease, cytopaenias or symptoms 
due to the IgM monoclonal protein are considered to 
have indolent disease and have no need for immediate 
treatment. Fifty percent of these patients will not require 
therapy within the first three years.26,27 Observational 
studies have proven that the watch-and-wait approach 
in asymptomatic patients is safe. Former studies have 
shown a better quality of life in those selected patients 
and no adverse effect on overall survival. There’s also no 
evidence of a negative influence on response to future 
therapy. However, follow-up should consist of clinical exa- 
mination and blood analysis every three to six months.28
Patients who need urgent therapy
Patients presenting with symptoms due to hypervis-
cosity, cryoglobulinemia or autoimmune related cyto-
paenias are in need of urgent treatment. The goal for 
these patients is to achieve a fast reduction of the 
IgM paraprotein, which can be reached by therapeutic 
plasma exchange (TPE). In case of hyperviscosity, red 
blood cell transfusion should be avoided or planned at 
the end of a TPE session to prevent an exacerbation of 
hyperviscosity. TPE is generally performed on a daily 
basis until symptoms subside or until plasma viscosity 
is normal. Because IgM is 80% intravascular serum, 
viscosity rises steeply with increasing IgM levels. Thus, 
a relatively small reduction in IgM concentration has 
a significant effect on lowering serum viscosity. TPE 
reduces viscosity by approximately 20-30% per session. 
Generally 1-1.5 plasma volumes are exchanged per ses-
sion. Fluid replacement usually consists of albumin. 
According to the American Society for Apheresis (ASFA) 
guidelines TPE is necessary for patients with sympto-
matic hyperviscosity due to a monoclonal gammopathy 
(evidence level category I, recommendation grade IB). 
TPE does not change the disease progression and 
termination of TPE will lead to a new rise of IgM. For 
this reason it is indicated to associate a general treatment 
as soon as possible.29,30
Frontline therapy
As stated earlier, there is no general agreement on the 
frontline therapy in WM patients. Several therapies 
have been shown to be effective as single agents or in 
combination schedules. Most treatment options are 
derived from other lymphoproliferative malignancies 
and include the use of alkylating agents, nucleoside 
analogues and rituximab. Other options are based on 
myeloma treatment. 
Due to the lack of randomised prospective trials we are 
also confronted with reimbursement issues in Belgium. 
Inclusion in clinical trials should be promoted for these 
patients at any time during disease evolution. 
Because of the long natural history of the disease the 
first treatment regimen should be chosen carefully, 
taking possible future treatments into account. There 
is a general agreement to avoid alkylating agents and 
nucleoside analogues in younger patients because of a 
possible risk of transformation to high grade lymphoma 
or therapy related myeloid malignancies and because 
of the toxic effects to stem cells.31,32
Rituximab as single agent and in combination with 
cyclophosphamide based regimens
The use of rituximab has become a standard of care in 
WM because of the low incidence of toxicities, the non-
myelosuppressive character and the absence of a toxic 
effect on stem cells. However, rituximab can be asso-
ciated with a paradoxical rise in IgM, the so-called 
IgM-flare phenomenon. Therefore one should be alert 
to hyperviscosity symptoms and the introduction of 
rituximab should be deferred in patients at risk for 
hyperviscosity (IgM above 40 g/L). Pre-emptive TPE 
before rituximab may be considered for patients with 
IgM ≥50 g/L (evidence level category I, recommendation 
grade IC) in order to avoid symptomatic IgM-flare. 
Rituximab as a single agent in first-line treatment is 
disappointing for patients with a high tumour burden. 
The response rate is not higher than 50% and there is 
only a limited effect on progression free survival (PFS).33,34 
However, rituximab as a single agent can be a good 
treatment option in low risk patients with moderate 
cytopaenia, IgM-related neuropathy or autoimmune 
mediated cytopaenia (unresponsive to corticosteroids). 
It is important to notice that the optimal response 
to rituximab may not be seen for months (twelve to 
eighteen months) and early evaluation may result in 
an underestimation of response. Combining rituximab 
with other agents improves response rates and PFS. 
As frontline treatment the majority of patients receive 
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a combination of rituximab with a cyclophosphamide 
based regimen: rituximab- cyclophosphamide- dexame-
thasone (R-CD) or rituximab- cyclophosphamide- pred-
nisolone (R-CP). These schedules give overall response 
rates of 70-80%, and complete responses in approxi-
mately 10% of patients.35-37 Despite the widespread use 
of CHOP, there has been a lot of debate about the 
necessity of including doxorubicin and even vincristine 
in the treatment for WM. Schedules without anthra-
cycline and vincristine have proven to be equally effec-
tive with fewer adverse events, particularly treatment- 
related neuropathy and febrile neutropaenia.36
Bortezomib
Bortezomib is a potent, reversible proteasome inhibitor. 
In vitro activity has been demonstrated in WM cell lines. 
A phase II trial using single agent bortezomib showed a 
25% reduction of IgM level in 78% of patients, generally 
seen during the first cycle. However, nodal response 
was less and overall response, considering IgM reduc-
tion with nodal response was only 26%.38 Bortezomib 
combinations have been evaluated as upfront therapy 
in two phase II studies. In a small trial, weekly bort-
ezomib (six cycles) in combination with rituximab 
during the first four cycles has shown response in 65% 
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of patients and median time to progression was not 
reached (at a median follow-up of fourteen months). 
Grade 3 and 4 toxicity was mainly haematological and 
no grade 3 or 4 neuropathy was seen (probably because 
of the weekly administration of bortezomib).39 In a recent 
update of a large phase II trial combining bortezomib, 
rituximab and dexamethasone (BRD), an overall response 
of 85% with a median PFS of 42 months was determined. 
The BRD regimen achieves rapid disease control with a 
median minimum response observed at 1.1 months.40 
Prophylaxis for herpes zoster infections is mandatory 
and patients should be carefully monitored for neuro-
pathy. Neuropathy was seen less frequently and was 
less serious when bortezomib was given weekly and/or 
subcutaneously. 
Nucleoside analogues
Nucleoside analogues have been used as monotherapy 
for the treatment of WM and have been proven to be 
effective both as frontline and as salvage therapy. In a 
phase III trial, oral fludarabine was superior to chloram-
bucil in newly diagnosed WM with an overall response 
rate of 48%, a median PFS of 36.3 months and a duration 
of response of 38.3 months.41
Combining fludarabine with rituximab enhances the 
response rate to 86% and the median PFS to 51 months.42
Tedeschi et al. reported a response rate of 79%, with 
12% complete remission and 21% very good partial re-
sponse in a group of 43 patients with symptomatic 
WM treated with fludarabine, cyclophosphamide and 
rituximab.43 The addition of cyclophosphamide might 
however evoke more adverse events (grade 3/4 neutro-
penia in 44% of the patients). 
Retrospective studies warned about a higher incidence of 
disease transformation (6%) and development of tMDS/
AML (1.5%) with the use of nucleoside analogues.31 
The fifteen year probabilities of developing disease 
transformation or tMDS/AML was respectively 21% and 
8% in patients treated with nucleoside analogues. A 
recent phase III trial (chlorambucil versus fludarabine) 
did not confirm these data but the median follow-up in 
this trial was 36 months.41
Nucleoside analogues should also be avoided in patients 
eligible for autologous SCT because they might impede 
stem cell mobilisation.44 Nevertheless, response rates 
with fludarabine combinations are high, even in patients 
with relapsed or refractory WM and the duration of 
response is long. Therefore, fludarabine-based combi-
nations could be considered in patients with relapsed/
refractory WM with a good performance status.
Alkylating agents
Bendamustine
Bendamustine is an old alkylating agent with nucleo-
side analogue properties that has recently been redis-
covered. A trial by Rummel et al. showed the results of 
22 WM patients treated with bendamustine-rituximab 
(BR) and nineteen patients treated with R-CHOP as 
first-line therapy.45 Responses were similar (95% in 
both arms with 60% complete response), but BR was 
superior in terms of median PFS (69.5 versus 28.1 
months) and toxicity was generally lower than seen 
with R-CHOP. Regarding stem cell harvest, after six 
cycles of BR, the CD34+ yield was similar to that after 
R-CHOP.53 Other clinical trials with bendamustine as 
a treatment option for low grade lymphoma, including 
patients with WM, revealed similar results. Therefore, 
BR is now a primary treatment option, especially for 
patients with high tumour bulk. 
Chlorambucil
For older, unfit patients presenting with slow progressing 
disease, chlorambucil may still be an option because of 
the good tolerance and ambulatory follow-up. Two pros-
pective trials explored the use of chlorambucil as single 
agent. In the trial of Leblond et al., the ORR of chloram-
bucil was 38.6% with a median PFS of 27.1 months.41 
Figure 2. Treatment algortihm for relapse/refractory disease. 
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The second trial, comparing continuous or pulse therapy 
noted a response rate of 79% in the patients with con-
tinuous treatment.46 Responses are slow and treatment 
should often continue longer than six months. 
Immunomodulatory drugs
Thalidomide
The Waldenström’s Macroglobulinaemia Clinical Trials 
Group (WMCTG) conducted a trial with thalidomide 
(400 mg/day) in combination with rituximab (eight 
administrations). Responses were comparable to immu-
nochemotherapy and varied between 70-80%. Median 
PFS was three years. However, frequent neuropathy 
necessitated thalidomide dose reductions or therapy 
discontinuation. 
Because of the low level of myelotoxicity, thalidomide-
rituximab is a good treatment option for patients 
presenting with myelosupression.47,48
Lenalidomide
Lenalidomide was also tested in combination with ritu-
ximab. However, the trial was prematurely terminated 
because of serious adverse events (acute, severe anae-
mia).49 It is advised not to use lenalidomide in WM 
outside clinical trials.
Treatment of relapsed or refractory disease
Treatment options for patients with relapsed disease 
include reinstitution of the initial treatment, switch to 
an alternative treatment regimen or high dose chemo-
therapy followed by autologous SCT. Patients should 
be encouraged to participate in clinical trials if available.
A possible algorithm for the treatment of patients with 
relapsed disease is presented in Figure 2. 
Autologous SCT
Several clinical studies have examined the feasibility 
and safety of high dose conditioning regimens followed 
by autologous SCT. The European Bone Marrow Trans-
plant Registry (EBMTR) reported the results of 202 
patients who received an autologous SCT. The five year 
PFS and overall survival rates were 31% and 61%, res-
pectively. The treatment-related mortality was 6%.47 
Other smaller trials showed similar results. Chemosen-
sitivity at the moment of autologous SCT was the most 
important prognostic factor for non-relapse mortality 
(NRM), response rate, PFS and overall survival.50 Auto-
logous SCT is a valuable option for younger patients 
with relapsing high risk disease. As part of primary 
therapy, autologous SCT could be considered in selected 
young patients with high risk IPSSWM and elevated 
lactate dehydrogenase.53 Patients with ≥3 lines of prior 
therapy appear to have limited benefit from autologous 
SCT. 
Allogeneic SCT
Information regarding allogeneic SCT in WM is limited. 
Initial series included mainly heavily pretreated patients 
and used myeloablative conditioning (MAC). In those 
small series, long-term CR was reported suggesting a 
graft-versus-WM effect, but this was associated with 
high transplant-related mortality (40%). The Lymphoma 
Working Party of the EBMT recently published a large 
series of 86 patients that underwent allogeneic SCT.52 
The conditioning was myeloablative in 37 patients and 
reduced-intensity (RIC) in 49 patients. Overall response 
rate was 75.6%. PFS and OS at five years was 56% and 
62% for MAC and 49% and 64% for RIC, respectively. 
NRM at three years was 33% for MAC and 23% for 
RIC. Chronic GVHD was associated with higher NRM, 
but also with lower relapse rate. In general this trans-
lated into an improvement of PFS (non significant).50,51
Given the advanced stage of the disease (55% had failed 
three or more lines of therapy) these results should 
be considered as promising and confirmed the graft-
versus-WM effect. Therefore, allogeneic SCT can be 
considered as a treatment option for younger high risk 
patients who have a good performance status and with 
relapse/refractory disease. However, taking into account 
all the new treatment options and the high morbidity 
and mortality associated with allogeneic SCT, this should 
be performed in a clinical trial when possible.50
Future perspectives
Several novel agents are currently under study in 
relapse/refractory WM patients.
Everolimus
Everolimus is an oral inhibitor of the mTOR pathway. 
Long-term results of a phase II study of everolimus 
were recently reported in a large cohort of patients with 
relapsed/refractory WM. The overall response rate was 
50% and 23% of patients achieved a major response. 
Clinical benefit was seen in 73% of the patients. The 
median duration of response has not been reached and 
median PFS was 21 months. At one year, 67% of patients 
remain progression free.54 Tolerance to therapy in this 
series was good, and a clinical trial examining the 
activity of everolimus in previously untreated patients 
with WM has recently been initiated. 
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Novel proteasome inhibitors (Carfilzomib)
Carfilzomib, a second-generation proteasome inhibitor, 
was recently evaluated in combination with rituximab 
and dexamethasone (CaRD), mainly in untreated WM 
patients. The schedule of carfilzomib was attenuated 
(days 1, 2, 8, and 9) compared to myeloma dosing, and 
maintenance therapy (days 1 and 2 only) was given every 
eight weeks for eight cycles. The overall response rate 
was 87% with a PFS of 65% after a median follow-up 
of 15.4 months. CaRD therefore represents a novel 
neuropathy-sparing option for proteasome inhibitor-
based therapy for WM.                     
Ofatumumab
Ofatumumab, a fully human monoclonal anti-CD20 anti-
body, was investigated as first-line treatment in relapsed/
refractory patients. Responses were higher in treat-
ment-naïve (6/9, 67%) and rituximab-naïve (9/12, 75%) 
patients compared to rituximab-exposed patients (13/25, 
52%). Infusion-related reactions were common and, as 
with rituximab, IgM-flare was observed.56 Ofatumumab 
has a promising activity but more data are needed in 
rituximab-refractory disease and combinations with 
other agents are under investigation.
Ibrutinib
The identification of the common somatic mutation 
 
in MyD88 in WM offered the opportunity for a more 
targeted approach. Bruton’s tyrosine kinase (BTK) has 
a critical place in signalling transduction through the 
MyD88-IRAK signalling pathway. Ibrutinib, a selective 
BTK inhibitor, has shown high activity in MyD88- 
mutated cell lines. Treon et al. reported the preliminary 
results of ibrutinib in patients with relapsed/refractory 
disease at ASH 2013. With a median follow-up of six 
cycles, the best overall response rate was 81% (4 VGPR, 
32 PR, 15 MR), with a major response rate (PR or better) 
of 57.1% and a median time to response of four weeks.57 
Rapid reductions in IgM serum and improved haemo-
globin occurred in most patients receiving ibrutinib. 
Main adverse events were thrombocytopenia, neutro-
penia, stomatitis and bleeding. WHIM-like mutations 
in CXCR4 are present in 1/3 of patients with WM, and 
their expression induces BTK activity and confers 
decreased sensitivity to ibrutinib in WM cells.57,58 The 
use of CXCR4 inhibitors such as plerixafor might 
be promising for the treatment of WM patients with 
mutated CXCR4.
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Key messages for clinical practice
1. Waldenström’s macroglobulinaemia-patients without IgM-related pathology and/or organ dys-
function should be observed rather than treated.
2. Plasmapheresis should be considered in patients with symptomatic hyperviscosity and before 
the start of rituximab if IgM exceeds 50g/L, but also in patients with IgM-related neuropathy, 
severe cryoglobulinemia, and cold agglutinin disease. 
3. A rituximab-containing frontline treatment is recommended in symptomatic Waldenström’s macro-
globulinaemia. Depending on the clinical situation, R-CD, R-CP, BR, BRD and R-Thalidomide, are 
all efficacious treatment options. Single agent rituximab, oral fludarabine or chlorambucil may be 
considered in older patients with slow disease progression, poor performance status or major 
comorbidities.
4. Nucleoside analogues should be avoided in young patients.
5. At relapse, retreatment with the previous therapy may be appropriate depending on the duration 
of response and pre-existing toxicities.
6. Autologous SCT is a salvage therapy for selected patients with chemosensitive disease. The place 
of allogeneic SCT is less defined and should not be used outside a clinical trial setting. 
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